(NASDAQ: CTXR) Citius Pharmaceuticals's forecast annual revenue growth rate of 224.47% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.07%, and it is also forecast to beat the US market's average forecast revenue growth rate of 14.06%.
Citius Pharmaceuticals's revenue in 2026 is $5,611,409.On average, 3 Wall Street analysts forecast CTXR's revenue for 2026 to be $2,192,252,430, with the lowest CTXR revenue forecast at $2,106,270,981, and the highest CTXR revenue forecast at $2,256,738,517. On average, 3 Wall Street analysts forecast CTXR's revenue for 2027 to be $4,025,370,339, with the lowest CTXR revenue forecast at $3,867,518,062, and the highest CTXR revenue forecast at $4,143,690,916.
In 2028, CTXR is forecast to generate $5,143,238,990 in revenue, with the lowest revenue forecast at $4,941,737,126 and the highest revenue forecast at $5,294,777,176.